Alivus Life Sciences Ltd (ALIVUS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Alivus Life Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Please find enclosed herewith intimation for Analyst/Investor meeting.
Intimation · 04 Nov 2026, 1:10 am
Alivus Life Sciences Schedules One-on-One Investor Meetings in Mumbai Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has scheduled in-person, one-on-one investor and analyst meetings in Mumbai. Representatives of the company will meet Avarta Capital on 6th Nov'26, followed by individual meetings with BOI Mutual Fund and Bandhan Mutual Fund on 12th Nov'26.
Please find enclosed herewith intimation for Analyst/Investor Meet.
Intimation · 30 Oct 2026, 11:24 pm
Alivus Life Sciences Schedules Institutional Investor Meetings in Mumbai Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has scheduled in-person, one-on-one investor and analyst meetings in Mumbai under SEBI LODR Regulation 30. The company's representatives will meet with Edelweiss Mutual Fund and Steinberg Asset Management on 4th Nov'26, followed by meetings with Axis Max Life Insurance and Karma Capital on 6th Nov'26. The schedule and meeting mode remain subject to change based on exigencies from either party.
We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company.
Audio / Video · 30 Oct 2026, 8:51 pm
Alivus Life Sciences Releases Q2 FY27 Earnings Call Audio Recording Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has made available the audio recording of its Q2 FY27 earnings conference call conducted on 30th Oct'26. The company confirmed the disclosure under SEBI LODR Regulations and hosted the recording on its official website for investor access.
Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021"
Others (Uncategorized) · 30 Oct 2026, 1:27 am
Alivus Life Sciences Approves Equity Allotment Under ESOP Scheme 2021 On 29th Oct'26, the Board of Directors of Alivus Life Sciences approved the allotment of 1,95,833 equity shares of face value Rs. 2 each following the exercise of stock options under the Employee Stock Option Scheme, 2021. Consequently, the company's paid-up share capital expanded from 12,27,71,448 shares (Rs. 24,55,42,896) to 12,29,67,281 shares (Rs. 24,59,34,562).
Please find enclosed herewith Investor Presentation for Q2 FY26-27.
Investor Presentation · 30 Oct 2026, 1:05 am
Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion Alivus Life Sciences reported Q2 FY27 revenue from operations of ₹6,820 Mn, rising 16.0% YoY and 6.5% QoQ, driven by a 20.8% YoY surge in non-GPL revenue to ₹5,369 Mn (79% of total). EBITDA surged 47.0% YoY to ₹2,851 Mn, with EBITDA margin expanding 880 bps YoY to 41.8% on operational efficiencies and favorable mix. PAT rose 51.3% YoY to ₹1,968 Mn. Strong free cash flow of ₹2,702 Mn lifted cash balances to ₹10,116 Mn as of 30th Sep'26. Total reactor capacity is projected to expand from 1,424 KL to 2,150 KL by FY27E.
Please find enclosed Press Release of the Company for the Second Quarter and Half Year ended September 30, 2026.
Press Release · 30 Oct 2026, 1:03 am
Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth Alivus Life Sciences reported Q2FY27 revenue of Rs 6,820 Mn, up 16.0% YoY, led by a 20.8% YoY rise in non-GPL business. EBITDA surged 47.0% YoY to Rs 2,851 Mn with record margins of 41.8% (up 880 bps YoY, 520 bps QoQ), driven by operating leverage and favorable product mix. PAT rose 51.3% YoY to Rs 1,968 Mn. As of 30th Sep'26, cash and equivalents stood at Rs 10,116 Mn. Solapur capex remains on track for completion across Q3-Q4FY27.
Please find enclosed Unaudited Financial Results for the Second quarter and Half Year ended September 30, 2026.
Outcome · 30 Oct 2026, 12:59 am
Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 12:51 am
Please find enclosed Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2026.
Financial Result · 30 Oct 2026, 12:51 am
Alivus Life Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 6,820 (+16.0% YoY | +6.5% QoQ) ■ EBITDA: 2,652 (+48.0% YoY | +25.3% QoQ) ■ EBITDA Margin (%): 38.9 (+841 bps YoY | +583 bps QoQ) ■ PAT: 1,967 (+51.3% YoY | +22.9% QoQ) ■ EPS (INR): 16.0 (+51.0% YoY | +22.8% QoQ)
Please find enclosed herewith details of Earnings Call slated for Friday, October 30, 2026.
Intimation · 30 Oct 2026, 8:30 am
Alivus Life Sciences Schedules Q2 FY27 Earnings Conference Call Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) will host its Q2 FY27 earnings conference call on Friday, 30th Oct'26, from 8:30 a.m. to 9:30 a.m. IST to discuss financial performance. Universal dial-in numbers for participants are +91 22 6280 1564 and +91 22 7115 8394, alongside international toll-free and toll access across key global locations including the USA, UK, Singapore, Hong Kong, and Japan. Pre-registration is available, with investor relations managed via Ernst & Young.
Alivus Life Sciences Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
Inter-alia to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 29 Oct 2026, 5:30 am
Alivus Life Sciences Board to Consider Q2FY27 Results on 29th Oct'26 Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has scheduled a Board of Directors meeting on 29th Oct'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the company's trading window for designated persons remains closed from 1st Oct'26 to 31st Oct'26 (both days inclusive) in compliance with SEBI insider trading regulations.
Kindly refer the attachment.
Others (Uncategorized) · 09 Oct 2026, 9:29 pm
Alivus Life Sciences Receives CGST Order with Tax and Penalty Demand Alivus Life Sciences received an order dated 8th Oct'26 under Section 74(1) of the CGST Act, 2017 from the Central GST Department, Ankleshwar. The demand covers FY 2020-21 and FY 2021-22, involving a tax amount of Rs. 25,61,400, an equivalent penalty of Rs. 25,61,400, and applicable interest. The company stated that the order has no material impact on its financials, operations, or other activities, and it is currently evaluating steps to exercise its right to appeal.
We would like to inform that the Company has acquired 9.21% stake in Torrent Urja 19 Private Limited.
Others (Uncategorized) · 07 Oct 2026, 10:46 pm
Alivus Life Sciences Acquires 9.21% Stake in Torrent Urja 19 Alivus Life Sciences Limited has acquired a 9.21% equity stake in Torrent Urja 19 Private Limited, an SPV under Torrent Green Energy Private Limited, for a cash consideration of Rs 14.04 crore against an authorized investment limit of up to Rs 16 crore. The strategic acquisition satisfies regulatory captive user requirements under the Electricity Act, 2003, enhancing renewable power usage to advance the company's 2030 carbon-neutrality target. Additionally, promoter Nirma Limited holds a 16.99% stake in the solar energy SPV.
Please find enclosed herewith intimation with respect to incorporation of wholly owned subsidiary of the Company in Brazil.
Others (Uncategorized) · 16 Sept 2026, 6:47 pm
Alivus Life Sciences Incorporates Wholly Owned Pharmaceutical Subsidiary in Brazil Alivus Life Sciences Limited incorporated a wholly owned subsidiary, Alivus Life Sciences Do Brasil Ltda., in Sao Paulo, Brazil, on 15th Sep'26. The new entity operates within the pharmaceutical industry. Alivus will hold 100% of the paid-up share capital via cash consideration, subscribing to an amount not exceeding R$ 500,000 across 500,000 shares. The incorporation has been approved by the Federative Republic of Brazil National Registrar of Legal Entities and does not fall under related-party transaction purview.
Enclosed please find herewith details of Investor meet.
Intimation · 11 Sept 2026, 8:08 pm
Alivus Life Sciences to Attend Kotak Healthcare Forum 2026 Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced that company representatives will participate in the Kotak Healthcare Forum 2026 on 17th Sep'26 in Mumbai. The event will feature in-person group and one-on-one investor/analyst meetings, subject to potential scheduling changes.
Please find attached herewith Scrutinizer''s Report.
Annual General Meeting · 09 Sept 2026, 1:49 am
Alivus Life Sciences 15th AGM Approves Dividend and Growth Strategy Alivus Life Sciences concluded its 15th AGM on 8th Sep'26, passing all four ordinary resolutions with requisite majorities. Key approvals include the FY26 audited financial statements, a final dividend of Rs. 5 per equity share, the reappointment of Director Hiren Patel, and the ratification of Cost Auditor remuneration for FY27. Management highlighted FY26 revenue growth, record profitability, and strong cash generation while detailing future expansion driven by an "API+" strategy and continued investments in manufacturing, R&D, and advanced pharmaceutical capabilities.
Please find attached herewith proceedings of the 15th Annual General Meeting of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held on 8th September, 2026.
Annual General Meeting · 09 Sept 2026, 1:41 am
Enclosed please find herewith details of Investor meet.
Intimation · 08 Sept 2026, 4:09 am
Alivus Life Sciences Schedules Institutional Investor Meetings in Mumbai Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) will host in-person institutional investor and analyst meetings on 10th Sep'26 and 11th Sep'26 in Mumbai. The interactions will involve various mutual funds and institutions across group and one-on-one formats, subject to scheduling changes.
Enclosed please find herewith Investor meet details.
Intimation · 06 Sept 2026, 1:45 am
Alivus Life Sciences Schedules One-on-One Institutional Investor Meetings in Mumbai Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) will conduct in-person, one-on-one investor and analyst meetings on 9th Sep'26 in Mumbai. The company is scheduled to interact with institutional entities comprising Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital, subject to any scheduling or mode adjustments due to operational exigencies.
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meetings
Intimation · 25 Aug 2026, 7:58 pm
Alivus Life Sciences Announces Schedule for Investor and Analyst Meetings Alivus Life Sciences has scheduled several one-on-one investor meetings. A virtual meeting with Mirae Asset (US) is set for Aug 28, '26. In-person meetings in Mumbai are planned with Emkay Global and SIMPL on Sep 01, '26. A subsequent virtual meeting with Lyptus Capital is scheduled for Sep 02, '26. The company noted that the schedule and mode of these meetings are subject to change based on exigencies. This disclosure was made on Aug 25, '26, as per SEBI regulations.
Enclosed please find herewith Press Release with respect to Acquisition.
Press Release · 18 Aug 2026, 11:03 pm
Alivus Life Sciences Acquires Majority Stake in IQGenX Pharma Alivus Life Sciences announced on 18 Aug'26 the acquisition of a 76% stake in IQGenX Pharma for INR 91.2 million. The deal expands Alivus' capabilities from APIs into advanced formulation development and CDMO services for oral solids, complex injectables, and ophthalmics. This strategic integration aims to leverage IQGenX’s platform, which serves regulated markets like the US and EU, to create a high-impact Oncology portfolio for out-licensing. The transaction is expected to close by the end of the current calendar year.
Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.
Others (Uncategorized) · 18 Aug 2026, 10:54 pm
Alivus Life Sciences to Acquire 76% Stake in IQGEN-X Pharma Alivus Life Sciences' board approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited on Aug 18, '26 for an aggregate consideration of approximately INR 9.12 crores. The deal expands Alivus' capabilities into API and CDMO spaces. The target entity, IQGEN-X, specializes in formulation development for regulated markets and reported a turnover of INR 3.48 crores for the year ended Mar 31, '26. The acquisition is expected to be completed by Dec 6, '26 and is a non-related party transaction.
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Intimation · 13 Aug 2026, 5:26 pm
Alivus Life Sciences Schedules Investor and Analyst Meetings Alivus Life Sciences has announced upcoming one-on-one investor/analyst meetings. On Aug 18, '26, the company will meet in-person with Green Lantern Capital and SIMPL in Mumbai. On Aug 19, '26, it will hold a virtual meeting with Burman Capital and an in-person meeting with Karma Capital in Mumbai. The schedule is subject to change.